New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
17:08 EDTBDSI, ENDPBioDelivery Sciences reports cash at end of FY12 $63.2M vs. $10.8M
BioDelivery Sciences (BDSI) ,BDSI's, research and development expenditures increased from $20.8M in 2011 to $35.4M in 2012. Revenues recognized in 2012 were $54.5M, including $35.8M from Endo (ENDP) and $17.5M previously deferred revenue associated with the BDSI commercialization agreement with Meda for BDSI's FDA approved product ONSOLIS. At the end of 2012, BDSI had $9.2M in deferred revenue associated with Endo, which will be recognized through 2013 and into early 2014 as clinical trials progress. BDSI reported net income of $1.7M or 5c per share for the twelve months ending December 31. That compares to a net loss of $23.3M or (82c) per share in 2011. At the end of 2012, BDSI had $63.2M in cash compared to $10.8M at December 31, 2011.
News For BDSI;ENDP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
10:05 EDTENDPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:11 EDTENDPMorgan Stanley ups Alkermes two notches with $85 price target
Subscribe for More Information
06:39 EDTENDPEndo downgraded to Equal Weight on growth uncertainty at Morgan Stanley
Subscribe for More Information
06:28 EDTENDPEndo downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
August 31, 2015
08:02 EDTENDPEndo announces Xiaflex for Dupuytren's contracture formal pricing in Japan
Endo announced that XIAFLEX for the treatment of Dupuytren's contracture has been listed on the Japanese National Health Insurance drug price standard. As a result, Endo partner Asahi Kasei Pharma expects to commercially launch the product in Japan on September 16, 2015. Under the terms of the partnership agreement, Endo will receive a $20M milestone payment upon the first commercial sale of XIAFLEX in Japan. In March 2011, Asahi Kasei Pharma received rights to develop and market XIAFLEX in Japan through an agreement with Auxilium Pharmaceuticals, which was subsequently acquired by Endo in January 2015. Under the agreement, Asahi Kasei Pharma was granted the exclusive right to commercialize XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's disease in Japan upon receipt of applicable regulatory approvals. Asahi Kasei Pharma is also responsible for clinical development and regulatory activities for XIAFLEX and has a right of first negotiation to obtain exclusive rights to commercialize other XIAFLEX(R) pipeline indications in Japan. Endo is eligible to receive up to $217M in remaining potential milestone payments and up to $210M in connection with the achievement of aggregate annual net sales thresholds. In addition, Asahi Kasei Pharma will provide tiered payments based on net sales of XIAFLEX . Asahi Kasei Pharma obtained approval in Japan for the manufacture and marketing of XIAFLEX(R) for Dupuytren's contracture in July 2015.
August 28, 2015
09:50 EDTENDPAllergan plans for generic version of Endo's Fortesta blocked, Bloomberg reports
A judge upheld Endo's (ENDP) patents on Fortesta expiring in 2018 and blocked Allergan's (AGN) bid to launch a generic version of the testosterone gel, according to Bloomberg.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use